Goldman Sachs
AKBA icon

Goldman Sachs’s Akebia Therapeutics AKBA Stock Holding History

Goldman Sachs’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,200
Closed -$166K – 5278
2020
Q2 		$166K Buy
+12,200
New +$126K ﹤0.01% 4856

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs's AKBA Position: Q1 2026 in Review

Goldman Sachs reduced its Akebia Therapeutics (AKBA) stake by 23% in Q1 2026, selling an estimated $1.52M and leaving 3,602,827 shares worth $5.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3690.

Goldman Sachs first reported a position in AKBA in Q2 2015 and has held it in 42 quarters since. The position peaked at $15.4M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Goldman Sachs held 3,602,827 shares of Akebia Therapeutics worth $5.01M as of Q1 2026.
  • Goldman Sachs sold 1,103,610 Akebia Therapeutics shares in Q1 2026, an estimated $1.52M.
  • Akebia Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3690 holding.
  • Goldman Sachs first reported a position in Akebia Therapeutics in Q2 2015 and has held it in 42 quarters since.
  • Goldman Sachs's Akebia Therapeutics position peaked at $15.4M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.